{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:54:46Z","timestamp":1787950486795,"version":"build-2784847793"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Amnestic mild cognitive impairment (MCI) is a prodromal stage of dementia, with a higher incidence of these patients progressing to Alzheimer\u2019s disease (AD) than normal aging people. A biomarker for the early detection and prediction for this progression is important. We recruited MCI subjects in three teaching hospitals and conducted longitudinal follow-up for 5 years at one-year intervals. Cognitively healthy controls were recruited for comparisom at baseline. Plasma transthyretin (TTR) levels were measured by ELISA. Survival analysis with time to AD conversion as an outcome variable was calculated with the multivariable Cox proportional hazards models using TTR as a continuous variable with adjustment for other covariates and bootstrapping resampling analysis. In total, 184 MCI subjects and 40 sex- and age-matched controls were recruited at baseline. At baseline, MCI patients had higher TTR levels compared with the control group. During the longitudinal follow-ups, 135 MCI patients (73.4%) completed follow-up at least once. The TTR level was an independent predictor for MCI conversion to AD when using TTR as a continuous variable (p\u2009=\u20090.023, 95% CI 1.001\u20131.007). In addition, in MCI converters, the TTR level at the point when they converted to AD was significantly lower than that at baseline (328.6\u2009\u00b1\u200966.5 vs. 381.9\u2009\u00b1\u200977.6\u2009ug\/ml, p\u2009&lt;\u20090.001). Our study demonstrates the temporal relationship between the plasma TTR level and the conversion from MCI to AD.<\/jats:p>","DOI":"10.1038\/s41598-019-55318-0","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T11:03:32Z","timestamp":1575975812000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Plasma Transthyretin as a Predictor of Amnestic Mild Cognitive Impairment Conversion to Dementia"],"prefix":"10.1038","volume":"9","author":[{"given":"Yi-Ting","family":"Tien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3720-4539","authenticated-orcid":false,"given":"Wei-Ju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chu","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Fu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Ming","family":"Jhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuu-Jiun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9135-3351","authenticated-orcid":false,"given":"Jong-Ling","family":"Fuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,10]]},"reference":[{"key":"55318_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jalz.2012.11.007","volume":"9","author":"M Prince","year":"2013","unstructured":"Prince, M. et al. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer\u2019s & dementia: the journal of the Alzheimer\u2019s Association 9, 63\u201375.e62, https:\/\/doi.org\/10.1016\/j.jalz.2012.11.007 (2013).","journal-title":"Alzheimer\u2019s & dementia: the journal of the Alzheimer\u2019s Association"},{"key":"55318_CR2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/archneur.56.3.303","volume":"56","author":"RC Petersen","year":"1999","unstructured":"Petersen, R. C. et al. Mild cognitive impairment: clinical characterization and outcome. Archives of neurology 56, 303\u2013308 (1999).","journal-title":"Archives of neurology"},{"key":"55318_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/archneur.61.1.59","volume":"61","author":"M Grundman","year":"2004","unstructured":"Grundman, M. et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Archives of neurology 61, 59\u201366, https:\/\/doi.org\/10.1001\/archneur.61.1.59 (2004).","journal-title":"Archives of neurology"},{"key":"55318_CR4","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2174\/1567205015666180202095616","volume":"15","author":"A Martinez-Torteya","year":"2018","unstructured":"Martinez-Torteya, A. et al. Identification and Temporal Characterization of Features Associated with the Conversion from Mild Cognitive Impairment to Alzheimer\u2019s Disease. Current Alzheimer research 15, 751\u2013763, https:\/\/doi.org\/10.2174\/1567205015666180202095616 (2018).","journal-title":"Current Alzheimer research"},{"key":"55318_CR5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3233\/jad-130881","volume":"38","author":"G Gainotti","year":"2014","unstructured":"Gainotti, G., Quaranta, D., Vita, M. G. & Marra, C. Neuropsychological predictors of conversion from mild cognitive impairment to Alzheimer\u2019s disease. Journal of Alzheimer\u2019s disease: JAD 38, 481\u2013495, https:\/\/doi.org\/10.3233\/jad-130881 (2014).","journal-title":"Journal of Alzheimer\u2019s disease: JAD"},{"key":"55318_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jns.2016.08.011","volume":"369","author":"D Kondo","year":"2016","unstructured":"Kondo, D. et al. Characteristics of mild cognitive impairment tending to convert into Alzheimer\u2019s disease or dementia with Lewy bodies: A follow-up study in a memory clinic. Journal of the neurological sciences 369, 102\u2013108, https:\/\/doi.org\/10.1016\/j.jns.2016.08.011 (2016).","journal-title":"Journal of the neurological sciences"},{"key":"55318_CR7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2174\/1567205043332018","volume":"1","author":"RB Maccioni","year":"2004","unstructured":"Maccioni, R. B., Lavados, M., Maccioni, C. B. & Mendoza-Naranjo, A. Biological markers of Alzheimer\u2019s disease and mild cognitive impairment. Current Alzheimer research 1, 307\u2013314 (2004).","journal-title":"Current Alzheimer research"},{"key":"55318_CR8","doi-asserted-by":"crossref","unstructured":"Schreiber, G., Richardson, S. J. & Prapunpoj, P. Structure and expression of the transthyretin gene in the choroid plexus: a model for the study of the mechanism of evolution. Microscopy research and technique 52, 21-30, 10.1002\/1097-0029(20010101)52:1<21::aid-jemt4>3.0.co;2-z (2001).","DOI":"10.1002\/1097-0029(20010101)52:1<21::AID-JEMT4>3.0.CO;2-Z"},{"key":"55318_CR9","doi-asserted-by":"publisher","first-page":"R338","DOI":"10.1152\/ajpregu.1990.258.2.R338","volume":"258","author":"G Schreiber","year":"1990","unstructured":"Schreiber, G. et al. Thyroxine transport from blood to brain via transthyretin synthesis in choroid plexus. The American journal of physiology 258, R338\u2013345, https:\/\/doi.org\/10.1152\/ajpregu.1990.258.2.R338 (1990).","journal-title":"The American journal of physiology"},{"key":"55318_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/0305-0491(93)90235-W","volume":"105","author":"G Schreiber","year":"1993","unstructured":"Schreiber, G. et al. Transthyretin expression evolved more recently in liver than in brain. Comparative biochemistry and physiology. B, Comparative biochemistry 105, 317\u2013325 (1993).","journal-title":"Comparative biochemistry and physiology. B, Comparative biochemistry"},{"key":"55318_CR11","doi-asserted-by":"crossref","first-page":"11793","DOI":"10.1016\/S0021-9258(17)39100-7","volume":"260","author":"DR Soprano","year":"1985","unstructured":"Soprano, D. R., Herbert, J., Soprano, K. J., Schon, E. A. & Goodman, D. S. Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat. The Journal of biological chemistry 260, 11793\u201311798 (1985).","journal-title":"The Journal of biological chemistry"},{"key":"55318_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.neurobiolaging.2005.02.010","volume":"27","author":"ZL Wu","year":"2006","unstructured":"Wu, Z. L. et al. Comparative analysis of cortical gene expression in mouse models of Alzheimer\u2019s disease. Neurobiology of aging 27, 377\u2013386 (2006).","journal-title":"Neurobiology of aging"},{"key":"55318_CR13","doi-asserted-by":"publisher","first-page":"12483","DOI":"10.1523\/JNEUROSCI.2417-11.2011","volume":"31","author":"X Li","year":"2011","unstructured":"Li, X., Masliah, E., Reixach, N. & Buxbaum, J. N. Neuronal production of transthyretin in human and murine Alzheimer\u2019s disease: is it protective? The Journal of neuroscience: the official journal of the Society for Neuroscience 31, 12483\u201312490 (2011).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"55318_CR14","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.febslet.2008.02.034","volume":"582","author":"R Costa","year":"2008","unstructured":"Costa, R., Goncalves, A., Saraiva, M. J. & Cardoso, I. Transthyretin binding to A-Beta peptide\u2013impact on A-Beta fibrillogenesis and toxicity. FEBS letters 582, 936\u2013942, https:\/\/doi.org\/10.1016\/j.febslet.2008.02.034 (2008).","journal-title":"FEBS letters"},{"key":"55318_CR15","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3233\/jad-2011-110611","volume":"28","author":"L Velayudhan","year":"2012","unstructured":"Velayudhan, L. et al. Plasma transthyretin as a candidate marker for Alzheimer\u2019s disease. Journal of Alzheimer\u2019s disease: JAD 28, 369\u2013375, https:\/\/doi.org\/10.3233\/jad-2011-110611 (2012).","journal-title":"Journal of Alzheimer\u2019s disease: JAD"},{"key":"55318_CR16","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2174\/156720512803251057","volume":"9","author":"CA Ribeiro","year":"2012","unstructured":"Ribeiro, C. A. et al. Transthyretin decrease in plasma of MCI and AD patients: investigation of mechanisms for disease modulation. Current Alzheimer research 9, 881\u2013889 (2012).","journal-title":"Current Alzheimer research"},{"key":"55318_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3233\/jad-2011-102145","volume":"25","author":"SH Han","year":"2011","unstructured":"Han, S. H. et al. Human serum transthyretin levels correlate inversely with Alzheimer\u2019s disease. Journal of Alzheimer\u2019s disease: JAD 25, 77\u201384, https:\/\/doi.org\/10.3233\/jad-2011-102145 (2011).","journal-title":"Journal of Alzheimer\u2019s disease: JAD"},{"key":"55318_CR18","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen, R. C. Mild cognitive impairment as a diagnostic entity. Journal of internal medicine 256, 183\u2013194, https:\/\/doi.org\/10.1111\/j.1365-2796.2004.01388.x (2004).","journal-title":"Journal of internal medicine"},{"key":"55318_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2796.2004.01380.x","volume":"256","author":"B Winblad","year":"2004","unstructured":"Winblad, B. et al. Mild cognitive impairment\u2013beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of internal medicine 256, 240\u2013246, https:\/\/doi.org\/10.1111\/j.1365-2796.2004.01380.x (2004).","journal-title":"Journal of internal medicine"},{"key":"55318_CR20","doi-asserted-by":"crossref","unstructured":"Wechsler D. Wechsler Adult Intelligence Scale. 3rd ed. San Antonio, TX: The Psychological Corporation; 1997.","DOI":"10.1037\/t49755-000"},{"key":"55318_CR21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein, M. F., Folstein, S. E. & McHugh, P. R. Mini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. Journal of psychiatric research 12, 189\u2013198 (1975).","journal-title":"Journal of psychiatric research"},{"key":"55318_CR22","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris, J. C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412\u20132414 (1993).","journal-title":"Neurology"},{"key":"55318_CR23","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1300\/J018v05n01_09","volume":"5","author":"JI Sheikh","year":"1986","unstructured":"Sheikh, J. I. 9\/Geriatric Depression Scale (GDS) AU - Yesavage, Jerome A. Clinical Gerontologist 5, 165\u2013173, https:\/\/doi.org\/10.1300\/J018v05n01_09 (1986).","journal-title":"Clinical Gerontologist"},{"key":"55318_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7, 263\u2013269, https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005 (2011).","journal-title":"Alzheimers Dement"},{"key":"55318_CR25","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.3324\/haematol.2013.100784","volume":"99","author":"J Delgado","year":"2014","unstructured":"Delgado, J., Pereira, A., Villamor, N., Lopez-Guillermo, A. & Rozman, C. Survival analysis in hematologic malignancies: recommendations for clinicians. Haematologica 99, 1410\u20131420, https:\/\/doi.org\/10.3324\/haematol.2013.100784 (2014).","journal-title":"Haematologica"},{"key":"55318_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3233\/JAD-2008-14102","volume":"14","author":"SF Gloeckner","year":"2008","unstructured":"Gloeckner, S. F. et al. Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. Journal of Alzheimer\u2019s disease: JAD 14, 17\u201325 (2008).","journal-title":"Journal of Alzheimer\u2019s disease: JAD"},{"key":"55318_CR27","doi-asserted-by":"publisher","first-page":"8368","DOI":"10.1073\/pnas.91.18.8368","volume":"91","author":"AL Schwarzman","year":"1994","unstructured":"Schwarzman, A. L. et al. Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proceedings of the National Academy of Sciences of the United States of America 91, 8368\u20138372 (1994).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"55318_CR28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/s1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr.","year":"2013","unstructured":"Jack, C. R. Jr. et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. The Lancet. Neurology 12, 207\u2013216, https:\/\/doi.org\/10.1016\/s1474-4422(12)70291-0 (2013).","journal-title":"The Lancet. Neurology"},{"key":"55318_CR29","doi-asserted-by":"publisher","first-page":"19423","DOI":"10.1523\/jneurosci.2561-13.2013","volume":"33","author":"X Li","year":"2013","unstructured":"Li, X. et al. Mechanisms of transthyretin inhibition of beta-amyloid aggregation in vitro. The Journal of neuroscience: the official journal of the Society for Neuroscience 33, 19423\u201319433, https:\/\/doi.org\/10.1523\/jneurosci.2561-13.2013 (2013).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"55318_CR30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/protein\/gzw008","volume":"29","author":"P Mangrolia","year":"2016","unstructured":"Mangrolia, P., Yang, D. T. & Murphy, R. M. Transthyretin variants with improved inhibition of beta-amyloid aggregation. Protein engineering, design & selection: PEDS 29, 209\u2013218, https:\/\/doi.org\/10.1093\/protein\/gzw008 (2016).","journal-title":"Protein engineering, design & selection: PEDS"},{"key":"55318_CR31","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/00007890-200107270-00023","volume":"72","author":"H Terazaki","year":"2001","unstructured":"Terazaki, H. et al. Variant transthyretin in blood circulation can transverse the blood-cerebrospinal barrier: qualitative analyses of transthyretin metabolism in sequential liver transplantation. Transplantation 72, 296\u2013299 (2001).","journal-title":"Transplantation"},{"key":"55318_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/srep20164","volume":"6","author":"M Alemi","year":"2016","unstructured":"Alemi, M. et al. Transthyretin participates in beta-amyloid transport from the brain to the liver\u2013involvement of the low-density lipoprotein receptor-related protein 1? Scientific reports 6, 20164, https:\/\/doi.org\/10.1038\/srep20164 (2016).","journal-title":"Scientific reports"},{"key":"55318_CR33","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-018-0297-y","volume":"25","author":"DA Nation","year":"2019","unstructured":"Nation, D. A. et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nature medicine 25, 270\u2013276, https:\/\/doi.org\/10.1038\/s41591-018-0297-y (2019).","journal-title":"Nature medicine"},{"key":"55318_CR34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3174\/ajnr.A1809","volume":"31","author":"KB Walhovd","year":"2010","unstructured":"Walhovd, K. B. et al. Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR. American journal of neuroradiology 31, 347\u2013354, https:\/\/doi.org\/10.3174\/ajnr.A1809 (2010).","journal-title":"AJNR. American journal of neuroradiology"},{"key":"55318_CR35","doi-asserted-by":"publisher","first-page":"369","DOI":"10.5114\/fn.2016.64815","volume":"54","author":"M Nesteruk","year":"2016","unstructured":"Nesteruk, M. et al. Combined use of biochemical and volumetric biomarkers to assess the risk of conversion of mild cognitive impairment to Alzheimer\u2019s disease. Folia neuropathologica 54, 369\u2013374, https:\/\/doi.org\/10.5114\/fn.2016.64815 (2016).","journal-title":"Folia neuropathologica"},{"key":"55318_CR36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/wnn.0000000000000119","volume":"30","author":"MA Clem","year":"2017","unstructured":"Clem, M. A. et al. Predictors That a Diagnosis of Mild Cognitive Impairment Will Remain Stable 3 Years Later. Cognitive and behavioral neurology: official journal of the Society for Behavioral and Cognitive Neurology 30, 8\u201315, https:\/\/doi.org\/10.1097\/wnn.0000000000000119 (2017).","journal-title":"Cognitive and behavioral neurology: official journal of the Society for Behavioral and Cognitive Neurology"},{"key":"55318_CR37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.neulet.2016.05.018","volume":"626","author":"L Zheng","year":"2016","unstructured":"Zheng, L. et al. Conversion from MCI to AD in patients with the APOE epsilon4 genotype: Prediction by plasma HCY and serum BDNF. Neuroscience letters 626, 19\u201324, https:\/\/doi.org\/10.1016\/j.neulet.2016.05.018 (2016).","journal-title":"Neuroscience letters"},{"key":"55318_CR38","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.biopsych.2017.02.007","volume":"83","author":"Y Shen","year":"2018","unstructured":"Shen, Y. et al. Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer\u2019s Disease Dementia in Individuals With Mild Cognitive Impairment. Biological psychiatry 83, 447\u2013455, https:\/\/doi.org\/10.1016\/j.biopsych.2017.02.007 (2018).","journal-title":"Biological psychiatry"},{"key":"55318_CR39","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.neuroimage.2014.10.002","volume":"104","author":"E Moradi","year":"2015","unstructured":"Moradi, E., Pepe, A., Gaser, C., Huttunen, H. & Tohka, J. Machine learning framework for early MRI-based Alzheimer\u2019s conversion prediction in MCI subjects. NeuroImage 104, 398\u2013412, https:\/\/doi.org\/10.1016\/j.neuroimage.2014.10.002 (2015).","journal-title":"NeuroImage"},{"key":"55318_CR40","doi-asserted-by":"publisher","first-page":"e01142","DOI":"10.1002\/brb3.1142","volume":"8","author":"C Adamson","year":"2018","unstructured":"Adamson, C., Beare, R., Ball, G., Walterfang, M. & Seal, M. Callosal thickness profiles for prognosticating conversion from mild cognitive impairment to Alzheimer\u2019s disease: A classification approach. Brain and behavior 8, e01142, https:\/\/doi.org\/10.1002\/brb3.1142 (2018).","journal-title":"Brain and behavior"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55318-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55318-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55318-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T17:18:17Z","timestamp":1671297497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55318-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,10]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["55318"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-55318-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,10]]},"assertion":[{"value":"11 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18691"}}